FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312738049> ?p ?o ?g. }

• W4312738049 endingPage "1759720X2211423" @default.
• W4312738049 startingPage "1759720X2211423" @default.
• W4312738049 abstract "Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA).To assess fracture risk in tofacitinib RA clinical trials.Post hoc analysis.We analyzed pooled data of phase I/II/III and long-term extension studies ('P123LTE cohort'), pooled data of placebo-controlled portions of phase III studies (phase III placebo-controlled cohort), and data from ORAL Surveillance [phase IIIb/IV randomized, open-label trial evaluating tofacitinib 5/10 mg twice daily (BID) vs tumor necrosis factor inhibitor (TNFi) in patients ⩾ 50 years with ⩾ 1 additional cardiovascular risk factor].In the phase III placebo-controlled cohort, incidence rates (IRs) [95% confidence interval (CI)] of fracture were 2.11 (1.09-3.68), 2.56 (1.23-4.71), and 4.43 (1.78-9.12) per 100 patient-years (PYs) for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively [tofacitinib 5 mg BID vs placebo: hazard ratio (HR) (95% CI) = 0.55(0.18-1.65); tofacitinib 10 mg BID vs placebo: HR (95% CI) = 0.72 (0.26-2.01)]. In P123LTE, IRs (95% CI) were 2.62 (2.29-2.99) and 2.26 (2.02-2.52) per 100 PY for average tofacitinib 5 and 10 mg BID, respectively. In ORAL Surveillance, IRs (95% CI) were 2.79 (2.34-3.30), 2.87 (2.40-3.40), and 2.27 (1.87-2.74) per 100 PY for tofacitinib 5 mg BID, tofacitinib 10 mg BID, and TNFi, respectively. In ORAL Surveillance, the risk of fracture was numerically higher than TNFi for tofacitinib 5 mg BID [HR (95% CI) = 1.23 (0.96-1.58)] and tofacitinib 10 mg BID [HR (95% CI) = 1.26 (0.97-1.62)]. In ORAL Surveillance, independent predictors of all and osteoporotic fractures with tofacitinib or TNFi included age ⩾ 65, female sex, history of fracture/osteoporosis, and baseline oral corticosteroid use.This post hoc analysis showed numerically lower fracture risk with tofacitinib versus placebo and numerically greater risk versus TNFi. We did not identify any tofacitinib-specific predictors of fractures, and predictors of fracture were generally aligned with prior literature in the general population and patients with RA. Patients with fracture risk factors should be adequately monitored and treated.NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT02831855, NCT00413699, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT00661661, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT01262118, NCT01484561, NCT02281552, NCT02147587, NCT02092467." @default.
• W4312738049 created "2023-01-05" @default.
• W4312738049 creator A5006565253 @default.
• W4312738049 creator A5008763926 @default.
• W4312738049 creator A5020336242 @default.
• W4312738049 creator A5021186697 @default.
• W4312738049 creator A5032746200 @default.
• W4312738049 creator A5038627121 @default.
• W4312738049 creator A5064025296 @default.
• W4312738049 creator A5066271822 @default.
• W4312738049 creator A5087625951 @default.
• W4312738049 date "2022-01-01" @default.
• W4312738049 modified "2023-10-16" @default.
• W4312738049 title "Fracture in clinical studies of tofacitinib in rheumatoid arthritis" @default.
• W4312738049 cites W1849496697 @default.
• W4312738049 cites W1968873497 @default.
• W4312738049 cites W1977975617 @default.
• W4312738049 cites W1990264130 @default.
• W4312738049 cites W1996292920 @default.
• W4312738049 cites W2010402483 @default.
• W4312738049 cites W2014927306 @default.
• W4312738049 cites W2019022588 @default.
• W4312738049 cites W2026501444 @default.
• W4312738049 cites W2035715328 @default.
• W4312738049 cites W2041429274 @default.
• W4312738049 cites W2047219483 @default.
• W4312738049 cites W2060483733 @default.
• W4312738049 cites W2060551064 @default.
• W4312738049 cites W2061624161 @default.
• W4312738049 cites W2063817656 @default.
• W4312738049 cites W2078787982 @default.
• W4312738049 cites W2088306841 @default.
• W4312738049 cites W2097506722 @default.
• W4312738049 cites W2108455224 @default.
• W4312738049 cites W2108529411 @default.
• W4312738049 cites W2109912666 @default.
• W4312738049 cites W2110768118 @default.
• W4312738049 cites W2111989549 @default.
• W4312738049 cites W2148644252 @default.
• W4312738049 cites W2150154492 @default.
• W4312738049 cites W2158332324 @default.
• W4312738049 cites W2170554139 @default.
• W4312738049 cites W2528417897 @default.
• W4312738049 cites W2734432177 @default.
• W4312738049 cites W2744427222 @default.
• W4312738049 cites W2932503135 @default.
• W4312738049 cites W2946145458 @default.
• W4312738049 cites W2946455726 @default.
• W4312738049 cites W2974930527 @default.
• W4312738049 cites W2990532942 @default.
• W4312738049 cites W3003321101 @default.
• W4312738049 cites W3003472716 @default.
• W4312738049 cites W3003839108 @default.
• W4312738049 cites W3006157754 @default.
• W4312738049 cites W3039149975 @default.
• W4312738049 cites W3044502797 @default.
• W4312738049 cites W3109937256 @default.
• W4312738049 cites W3112299642 @default.
• W4312738049 cites W3121477570 @default.
• W4312738049 cites W3126549826 @default.
• W4312738049 cites W3126792011 @default.
• W4312738049 cites W3190982299 @default.
• W4312738049 cites W3199740933 @default.
• W4312738049 cites W4210529991 @default.
• W4312738049 doi "https://doi.org/10.1177/1759720x221142346" @default.
• W4312738049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36601090" @default.
• W4312738049 hasPublicationYear "2022" @default.
• W4312738049 type Work @default.
• W4312738049 citedByCount "2" @default.
• W4312738049 countsByYear W43127380492023 @default.
• W4312738049 crossrefType "journal-article" @default.
• W4312738049 hasAuthorship W4312738049A5006565253 @default.
• W4312738049 hasAuthorship W4312738049A5008763926 @default.
• W4312738049 hasAuthorship W4312738049A5020336242 @default.
• W4312738049 hasAuthorship W4312738049A5021186697 @default.
• W4312738049 hasAuthorship W4312738049A5032746200 @default.
• W4312738049 hasAuthorship W4312738049A5038627121 @default.
• W4312738049 hasAuthorship W4312738049A5064025296 @default.
• W4312738049 hasAuthorship W4312738049A5066271822 @default.
• W4312738049 hasAuthorship W4312738049A5087625951 @default.
• W4312738049 hasBestOaLocation W43127380492 @default.
• W4312738049 hasConcept C126322002 @default.
• W4312738049 hasConcept C142724271 @default.
• W4312738049 hasConcept C204787440 @default.
• W4312738049 hasConcept C207103383 @default.
• W4312738049 hasConcept C27081682 @default.
• W4312738049 hasConcept C2776233030 @default.
• W4312738049 hasConcept C2777575956 @default.
• W4312738049 hasConcept C2778886723 @default.
• W4312738049 hasConcept C44249647 @default.
• W4312738049 hasConcept C71924100 @default.
• W4312738049 hasConcept C72563966 @default.
• W4312738049 hasConcept C90924648 @default.
• W4312738049 hasConceptScore W4312738049C126322002 @default.
• W4312738049 hasConceptScore W4312738049C142724271 @default.
• W4312738049 hasConceptScore W4312738049C204787440 @default.
• W4312738049 hasConceptScore W4312738049C207103383 @default.
• W4312738049 hasConceptScore W4312738049C27081682 @default.

• next